Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Queensland Health
QuintilesIMS
Cantor Fitzgerald
Express Scripts
Accenture
Harvard Business School
Merck
Boehringer Ingelheim
Colorcon

Generated: August 17, 2017

DrugPatentWatch Database Preview

Bristol Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL, and what generic alternatives to BRISTOL drugs are available?

BRISTOL has one hundred and ten approved drugs.

There are twenty-four US patents protecting BRISTOL drugs and there have been two Paragraph IV challenges on BRISTOL drugs in the past three years.

There are six hundred and fifty-six patent family members on BRISTOL drugs in fifty-nine countries.

Summary for Applicant: Bristol

Patents:24
Tradenames:87
Ingredients:74
NDAs:110
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
PRAVIGARD PAC (COPACKAGED)
aspirin; pravastatin sodium
TABLET, TABLET, TABLET;ORAL021387-004Jun 24, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
PROTAMINE ZINC INSULIN
insulin susp protamine zinc purified beef
INJECTABLE;INJECTION017928-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
GLUCOPHAGE
metformin hydrochloride
TABLET;ORAL020357-003Nov 5, 1998DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
CAPSULE;ORAL021567-003Jun 20, 2003ABRXYesNo► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
NARCAN
naloxone hydrochloride
INJECTABLE;INJECTION071083-001Jul 28, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bristol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-003Dec 31, 2002► Subscribe► Subscribe
Bristol Myers Squibb
BUSPAR
buspirone hydrochloride
TABLET;ORAL018731-002Sep 29, 1986► Subscribe► Subscribe
Bristol Myers Squibb
ZERIT
stavudine
CAPSULE;ORAL020412-002Jun 24, 1994► Subscribe► Subscribe
Bristol Myers Squibb
SUSTIVA
efavirenz
TABLET;ORAL021360-002Feb 1, 2002► Subscribe► Subscribe
Bristol Myers Squibb
BUSPAR
buspirone hydrochloride
TABLET;ORAL018731-004Apr 22, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BRISTOL drugs

Drugname Dosage Strength Tradename Submissiondate
apixaban
Tablets2.5 mg and 5 mg
ELIQUIS
12/28/2016
naloxone hydrochloride
Nasal Spray4 mg/spray
NARCAN
7/15/2016
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/17/2011
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/16/2011
dasatinib
Tablets20 mg, 50 mg, 70 mg and 100 mg
SPRYCEL
6/28/2010
entecavir
Tablets0.5 mg and 1 mg
BARACLUDE
6/14/2010
atazanavir sulfate
Capsules100 mg and 150 mg
REYATAZ
3/19/2010
atazanavir sulfate
Capsules200 mg
REYATAZ
2/16/2010
atazanavir sulfate
Capsules300 mg
REYATAZ
7/20/2009
efavirenz
Tablets600 mg
SUSTIVA
4/9/2009
pravastatin sodium
Tablets30 mg
PRAVACHOL
6/1/2005
didanosine
Delayed-release Capsules200 mg, 250 mg and 400 mg
VIDEX EC
6/1/2004

Non-Orange Book Patents for Bristol

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,858,616 Nitrogen containing heterobicycles as factor Xa inhibitors► Subscribe
9,227,961Hepatitis C virus inhibitors► Subscribe
8,188,120Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
7,371,761Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,989,391Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bristol Drugs

Country Document Number Estimated Expiration
Argentina061838► Subscribe
World Intellectual Property Organization (WIPO)2008010921► Subscribe
European Patent Office1610780► Subscribe
European Patent Office2487168► Subscribe
Portugal1427415► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bristol Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/049United Kingdom► SubscribePRODUCT NAME: STAVUDINE; REGISTERED: UK EU/1/96/009/001 19960508; UK EU/1/96/009/002 19960508; UK EU/1/96/009/003 19960508; UK EU/1/96/009/004 19960508; UK EU/1/96/009/005 19960508; UK EU/1/96/009/006 19960508; UK EU/1/96/009/007 19960508; UK EU/1/96/009/008 19960508; UK EU/1/96/009/009 19960508
/2016Austria► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND TENOFOVIR ALAFENAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE TENOFOVIR ALAFENAMID FUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 (MITTEILUNG) 20151123
C0007France► SubscribePRODUCT NAME: DACLATASVIR ET DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI,EN PARTICULIER LE SEL DE DICHLORHYDRATE DE DACLATASVIR; REGISTRATION NO/DATE: EU/1/14/939/001 20140826
213Luxembourg► SubscribePRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE
C0004Belgium► SubscribePRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Julphar
Johnson and Johnson
Argus Health
Cerilliant
US Department of Justice
Medtronic
US Army
Teva
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot